AstraZeneca started at buy at Goldman, which rates GSK a neutral
By Steve Goldstein
Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.
Analysts led by Rajan Sharma said AstraZeneca is its preferred name in European pharma as it started with a price target of 15,200 pence, or $97 per U.S.-listed share. AstraZeneca (UK:AZN) (AZN) rose 1% to 12,048 pence, extending year-to-date gains to 14%.
"We believe the company offers an attractive combination of a strong underlying business with room for margin expansion, coupled with an unrivaled pipeline optionality driven by a best-in-class pipeline and track record of execution," they said, calling the company an oncology powerhouse. They added the ex-oncology pipeline is potentially overlooked by the market.
On GSK, they set a 1,850 pence target, or $47 per ADR. The analysts said positive momentum is in the current price after spinning off Haleon, "exceptional execution" on vaccines Shingrix and Arexy, and consistent earnings growth.
Zantac litigation will remain an overhang on the stock, they added, with about 78,000 state court trials remaining,
"To drive a material re-rating from here, and in line with our stock selection framework, we believe pipeline delivery ex-vaccines will be required to provide the market with comfort that the transformation is on track and long-term targets are achievable," they said.
GSK shares (UK:GSK) (GSK) slipped 0.4% to 1,740 pence but has gained 20% this year.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-30-24 0634ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued